Editorial
John G. Gribben1 António Parreira2
1Barts and The London Queen Mary’s School of Medicine, University of London, UK, 2Portuguese Institute of Cancer, Lisbon, Portugal.
The advent of rituximab has dramatically changed the management of non-Hodgkin’s lymphoma (NHL), with a corresponding improvement in patient outcomes. After many years in which treatment strategies in NHL remained fairly static, rituximab has been associated with prolonged survival in follicular lymphoma (FL) and an increased cure rate in diffuse large B-cell lymphoma (DLBCL). Initial trials in chronic lymphocytic leukaemia (CLL) also show considerable promise. An opportunity to reflect on these advances, examine recently available clinical data and share experience of clinical practice was provided by the ‘Maintaining Life: Optimal Strategies to Improve Survival – Expert Investigator Forum 2007’.